EULAR 2024

Subclinical PsA - where is the border?

Difference in axial involvement in axSpA and axPsA

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

Handling cardiovascular risks in RA

Deeper B-cell depletion

Tapering or even stopping TNF inhibitors in pts. with sustained remission?!

JAK inhibitors in GCA - a good opportunity?

Avoiding overdiagnosis in axSpA

What advances the radiographic progression? IL-17A vs. TNF inhibition

Uterine inflammation in the pathogenesis in axSpA

Sooner or later - when therapy with biologics?

Treat-to-target approach to induce sustained clinical remission in early axSpA

Neuroinflammation as possible cause of intestinal dysbiosis in axSpA

Minimal spinal radiographic progression with Bimekizumab

Treat-to-target in axSpA - a long way to go!

Factors associated with spinal progression in axSpA

Früher oder später - wann Therapie mit Biologika?

Minimale Röntgenprogression der Wirbelsäule unter Bimekizumab

Ruolo dell’infiammazione uterina nella patogenesi dell’axSpA

Ruolo della neuroinfiammazione della patogensi dell’AxSpA

Vermeidung von Überdiagnose bei axSpA

Was treibt die Röntgenprogression an? IL-17A vs. TNF Inhibition

Approccio treat-to-target per indurre una remissione clinica sostenuto in early axSpA

Treat-to-target bei der axSpA - a long way to go!

Subclinical PsA - where is the border?

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

Difference in axial involvement in axSpA and axPsA

Cardiovascular outcome in PsA - TnF vs. IL-17 inhibitors

The difficult cases in PsA

Sonelokimab, a new molecule for IL-17A & IL-17F inhibition - first data on arthritis

Treatment strategy in early PsA - TnF inhibitors or not?

The JAK family is growing. Another Tyk2 inhibitor: safe - with a moderate effect

Early prediction by FAPI-PET in PsA

12-weeks results from the PRO-SPIRIT study

Managing comorbidities in PsA

Which treatment to prevent PsA from PsO?

Post-hoc analysis on severe disease activity in PsA

A new injection for knee osteoarthritis

Small molecules with a better enthesitis efficacy - new data on izokibep

A lot of steroids always help - no matter the concomitant medication...

A mouse model for PsA and PsO!

Valutazione della risposta a due anni di trattamento nei pazienti con Artrite Psoriasica con elevata attività di malattia

Rhumatisme psoriasique débutant : anti TNF ou pas?

Risultati a 12 settimane dello studio di Real World "PRO-SPIRIT"

Frühe Prädiktion durch FAPI-PET bei PsA

Viel Kortison hilft immer - Begleittherapie egal...

Quel traitement pour prévenir l’évolution du psoriasis vers un rhumatisme psoriasique?

Kleine Moleküle mit besserer Enthesitiswirkung - neue Daten zu Izokibep

Risque cardiovasculaire et rhumatisme psoriasique : anti TNF ou anti Interleukine 17?

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor: sicher - mit moderatem Effekt

Sonelokimab, ein neues Molekül zur IL-17A- & IL-17F-Inhibition - erste Daten zur Arthritis

Tapering or even stopping TNF inhibitors in pts. with sustained remission?!

Deeper B-cell depletion

Handling cardiovascular risks in RA

JAK inhibitors in GCA - a good opportunity?

New JAK inhibitor tested in a Phase III trial in China

Anti-citrullinated protein antibody (ACPA) does not predict response to abatacept in RA

Statins in RA - who benefits?

A model to predict progression from palindromic rheumatism to persistent arthritis

Abatacept vs adalimumab in dual seropositive RA patients with the shared epitope

Real-world data on safety of etanercept biosimilar

ARCTIC REWIND - Tapering not recommended in patients on TNF inhibitors in stable remission

Potential new treatment class in RA

Debate on regulatory safety measures for JAKies based on ORAL Surveillance study

Good news in RA

Tapering of TNF Inhibitors in RA Patients with sustained Remission

Debate on therapeutic drug monitoring

No new safety signals from the JAK-POT study

Statine bei der RA - wer profitiert?

Un modelo para predecir la progresión del reumatismo palindrómico a artritis persistente

En ny JAK hemmer undersøkt i en fase III studie I Kina

Reducción y suspensión de los inhibidores del TNF en pacientes con AR en remisión mantenida

Debatt om bruk av therapeutic drug monitoring (TDM, monitorering av legemiddelkonsentrasjoner) i klinisk praksis

Keine neuen Safety-Signale aus der JAK-POT Studie

Abatacept vs adalimumab en pacientes con AR doble seropositivos con el epitopo compartido

ARCTIC REWIND – dosereduksjon og seponering anbefales ikke hos pasienter i stabil remisjon under behandling med en TNF-hemmer

Debatt om regulatoriske krav om sikkerhet ved bruk av JAK hemmere basert på den publiserte ORAL Surveillance study

Upadacitinib in GCA

Upadacitinib bei RZA

AI in rheumatology

The role of rheumatoid factor from early to late

Holistic view on multidisciplinary care in rheumatology

How to treat Lupus: What's on the horizon?

Daratumumab in SLE

Daratumumab bei SLE